Joint effect of platelet distribution width and stent surface area on major adverse cardiovascular events after percutaneous coronary intervention

被引:2
|
作者
Zhang, Xiaofeng [1 ,2 ]
Ge, Haiyan [3 ]
Gong, Xiaoxuan [1 ]
Wang, Jing [1 ]
Li, Chunjian [1 ]
机构
[1] Nanjing Med Univ, Dept Cardiol, Affiliated Hosp 1, Nanjing, Peoples R China
[2] Nanjing Univ Chinese Med, Hosp Nanjing 2, Nanjing, Peoples R China
[3] Zhongshan Rehabil Hosp Jiangsu Prov, Dept Ultrasound, Nanjing, Peoples R China
关键词
Stent surface area(SSA); platelet distribution width (PDW); percutaneous coronary intervention (PCI); major adverse cardiovascular events (MACEs); DRUG-ELUTING STENTS; BARE METAL STENTS; ARTERY-DISEASE; MARKER; RISK;
D O I
10.21037/apm-21-1088
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: This study was conducted to analyze the influences of stent surface area (SSA), platelet distribution width (PDW), and the joint effect of these 2 risk factors on major adverse cardiovascular events (MACEs) in patients treated with percutaneous coronary intervention (PCI) together with drug-eluting stent (DES) implantation. Methods: Based on a cross-sectional survey conducted between 2011 and 2012, a prospective cohort study was enrolled consiting of 442 patients who had undergone PCI with DES implantation. We categorized the participants into 4 subgroups according to PDW and SSA. Cox proportional hazards models were applied to explore the correlation of PDW and SSA with MACE incidence. Results: During the 12 months of follow-up time, 87 patients experienced MACEs, which included 4 deaths (4.6%), 5 nonfatal myocardial infarctions (MIs) (5.75%), 9 ischemic strokes (10.34%), and 73 clinically relevant bleeding episodes (83.91%). The risks of MACEs were decreased by SSA and increased by PDW. However, the association of PDW or SSA with MACE was not statistically significant. Compared with the patients with PDW >= 13.5% and SSA <358.14 mm(2), the multivariable adjusted hazard ratios [HRs; 95% confience interval (CI)] of the total MACEs for the patients with PDW <13.5% and SSA >= 358.14 mm(2), and with PDW >= 13.5% and SSA >= 358.14 mm(2) were 0.94 (95% CI: 0.55-1.64) and 0.37 (95% CI: 0.18-0.76), respectively. Additionally, the patients in the group of PDW <13.5% and SSA <358.14 mm(2), and PDW >= 13.5% and SSA >= 358.14 mm(2) had respective HRs of 0.47 (95% CI: 0.24-0.91) and 0.28 (95% CI: 0.13-0.63) for 12-month bleeding events when PDW >= 13.5% and SSA <358.14 mm(2)was used as a group reference. Conclusions: Our present results suggest that the joint effect of PDW and SSA was significantly correlated to MACE development in the patients treated with PCI (with DES implantation).
引用
收藏
页码:5633 / 5640
页数:8
相关论文
共 50 条
  • [21] Prevention of cardiovascular events after percutaneous coronary intervention
    Herrmann, HC
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (26): : 2708 - 2710
  • [22] Intervention study of continuous nursing on recurrent adverse cardiovascular events in patients after percutaneous coronary intervention
    Liu, Qiaoling
    Liu, Zhiping
    Wei, Tanwei
    MINERVA SURGERY, 2023, 78 (03): : 337 - 339
  • [23] Sex and age differences of major cardiovascular events in patients after percutaneous coronary intervention
    Yang, Ya-Ling
    Chen, Su-Chan
    Wu, Cheng-Hsueh
    Huang, Shao-Sung
    Chan, Wan Leong
    Lin, Shing-Jong
    Chou, Chia-Yu
    Chen, Jaw-Wen
    Pan, Ju-Pin
    Charng, Min-Ji
    Chen, Ying-Hwa
    Wu, Tao-Cheng
    Lu, Tse-Min
    Hsu, Pai-Feng
    Huang, Po-Hsun
    Cheng, Hao-Min
    Huang, Chin-Chou
    Sung, Shih-Hsien
    Lin, Yenn-Jiang
    Leu, Hsin-Bang
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2023, 86 (12) : 1046 - 1052
  • [24] Effect of Insurance Type on Adverse Cardiac Events After Percutaneous Coronary Intervention
    Gaglia, Michael A., Jr.
    Torguson, Rebecca
    Xue, Zhenyi
    Gonzalez, Manuel A.
    Ben-Dor, Itsik
    Maluenda, Gabriel
    Mahmoudi, Michael
    Sardi, Gabriel
    Wakabayashi, Kohei
    Kaneshige, Kimberly
    Suddath, William O.
    Kent, Kenneth M.
    Satler, Lowell F.
    Pichard, Augusto D.
    Waksman, Ron
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 107 (05): : 675 - 680
  • [25] Stratification Analysis of Statin Effect on Major Adverse Cardiac Events After Percutaneous Coronary Intervention in Patients on Hemodialysis
    Horikoshi, Takeo
    Nakamura, Takamitsu
    Yoshizaki, Toru
    Nakamura, Jun
    Makino, Aritaka
    Saito, Yukio
    Obata, Jun-ei
    Sawanobori, Takao
    Takano, Hajime
    Umetani, Ken
    Watanabe, Akinori
    Asakawa, Tetsuya
    Kugiyama, Kiyotaka
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2022, 79 (02) : 168 - 176
  • [26] Effect of postmenopausal hormone therapy on major adverse cardiac events after percutaneous coronary intervention: The HERS trial
    Khan, MA
    Shlipak, MG
    Liu, MW
    Rogers, WJ
    Lin, F
    Hlatky, MA
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 56A - 56A
  • [27] Relation of Red Blood Cell Distribution Width to Risk of Major Adverse Cardiovascular Events, Death, and Effect of Alirocumab After Acute Coronary Syndrome
    Moriarty, Patrick M.
    Steg, Philippe G.
    Gorby, Lauryn K.
    Zeiher, Andreas M.
    White, Harvey D.
    Sourdille, Timothee
    Roe, Matthew T.
    Louie, Michael J.
    Jukema, J. Wouter
    Harrington, Robert A.
    Goodman, Shaun G.
    Diaz, Rafael
    Bittner, Vera A.
    Bhatt, Deepak L.
    Szarek, Michael
    Li, Helen
    Schwartz, Gregory G.
    CIRCULATION, 2019, 140
  • [28] Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes
    Moriarty, Patrick M.
    Steg, Philippe Gabriel
    McGinniss, Jennifer
    Zeiher, Andreas M.
    White, Harvey D.
    Manvelian, Garen
    Pordy, Robert
    Loy, Megan
    Jukema, J. Wouter
    Harrington, Robert A.
    V. Gray, Jessica
    Gorby, Lauryn K.
    Goodman, Shaun G.
    Diaz, Rafael
    Bittner, Vera A.
    Bhatt, Deepak L.
    Szarek, Michael
    Schwartz, Gregory G.
    ODYSSEY OUTCOMES Investigators
    JOURNAL OF CLINICAL LIPIDOLOGY, 2022, 16 (05) : 747 - 756
  • [29] Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial
    Legrand, Victor
    Cuisset, Thomas
    Chenu, Patrick
    Vrolix, Mathy
    Martinez, Christophe
    Dens, Joseph
    Gach, Olivier
    Boland, Jean
    Claeys, Marc J.
    Magne, Julien
    Barbato, Emanuele
    Wijns, William
    EUROINTERVENTION, 2014, 10 (02) : 204 - 211
  • [30] Platelet density per monocyte predicts adverse events in patients after percutaneous coronary intervention
    Rutten, Bert
    Roest, Mark
    McClellan, Elizabeth A.
    Sels, Jan W.
    Stubbs, Andrew
    Jukema, J. Wouter
    Doevendans, Pieter A.
    Waltenberger, Johannes
    van Zonneveld, Anton-Jan
    Pasterkamp, Gerard
    de Groot, Philip G.
    Hoefer, Imo E.
    THROMBOSIS AND HAEMOSTASIS, 2016, 115 (02) : 353 - 360